RBA Wealth Management LLC Has $4.84 Million Position in Becton, Dickinson and Company (NYSE:BDX)

RBA Wealth Management LLC lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,331 shares of the medical instruments supplier’s stock after buying an additional 604 shares during the quarter. Becton, Dickinson and Company comprises 1.8% of RBA Wealth Management LLC’s portfolio, making the stock its 23rd biggest holding. RBA Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $4,839,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares in the last quarter. Nordea Investment Management AB raised its holdings in Becton, Dickinson and Company by 31.0% during the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after purchasing an additional 673,568 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares during the period. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $108,243,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Becton, Dickinson and Company by 62.2% during the third quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock worth $266,974,000 after buying an additional 424,487 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BDX. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $283.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was sold at an average price of $236.51, for a total value of $141,196.47. Following the completion of the transaction, the executive vice president now directly owns 5,544 shares of the company’s stock, valued at $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 9,844 shares of company stock worth $2,210,716. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0 %

BDX opened at $247.57 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a market cap of $71.80 billion, a PE ratio of 41.68, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40. The company has a fifty day moving average of $230.53 and a 200-day moving average of $233.83. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.42 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Becton, Dickinson and Company declared that its board has approved a stock buyback program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.